CASTLE BIOSCIENCES, INC. (CSTL) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 357.28M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $357.28M | (m) | (m) |
| 2026-03-31 | (m) | $339.92M | (m) | (m) |
| 2025-12-31 | (m) | $344.23M | (m) | (m) |
| 2025-09-30 | (m) | $343.53M | (m) | (m) |
| 2025-06-30 | (m) | $346.27M | (m) | (m) |
| 2025-03-31 | (m) | $347.08M | (m) | (m) |
| 2024-12-31 | (m) | $332.07M | (m) | (m) |
| 2024-09-30 | (m) | $311.88M | (m) | (m) |
| 2024-06-30 | (m) | $287.59M | (m) | (m) |
| 2024-03-31 | (m) | $250.72M | (m) | (m) |
| 2023-12-31 | (m) | $219.79M | (m) | (m) |
| 2023-09-30 | (m) | $192.01M | (m) | (m) |
| 2023-06-30 | (m) | $167.52M | (m) | (m) |
| 2023-03-31 | (m) | $152.22M | (m) | (m) |
| 2022-12-31 | (m) | $137.04M | (m) | (m) |
| 2022-09-30 | (m) | $123.74M | (m) | (m) |
| 2022-06-30 | (m) | $110.20M | (m) | (m) |
| 2022-03-31 | (m) | $98.12M | (m) | (m) |
| 2021-12-31 | (m) | $94.08M | $15.82M | (m) |
| 2021-09-30 | (m) | $86.34M | (m) | (m) |
| 2021-06-30 | (m) | $78.09M | (m) | (m) |
| 2021-03-31 | $57.72M | $68.04M | $10.32M | 84.83% |
| 2020-12-31 | $52.96M | $62.65M | $9.69M | 84.54% |
| 2020-09-30 | $53.96M | $62.98M | $9.02M | 85.67% |
| 2020-06-30 | $54.29M | $62.54M | $8.26M | 86.80% |
| 2020-03-31 | $52.46M | $60.57M | $8.10M | 86.62% |
| 2019-12-31 | $44.55M | $51.87M | $7.31M | 85.91% |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2019-03-31 | $22.20M | $27.84M | (m) | 79.74% |
| 2018-12-31 | $17.49M | $22.79M | $5.30M | 76.75% |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |